As it is becoming increasingly evident that a mono‐therapeutic approach is unlikely to provide anti‐tumour efficacy, the combination of ACOD1 suppression in TAMs, which enables to harness both the innate and adaptive immune systems, together with the inhibition of immune checkpoints may advance therapeutic successes against GBM and other solid tumours. This evidence concerns the gene ACOD1 and glioblastoma.